Brought to you by 
Abcam pays $155mm for monoclonal antibody producer Epitomics
29 Mar 2012
Executive Summary
Abcam PLC has acquired fellow antibody research tools company, privately held Epitomics Inc., for $155mm. Half of the sum will be paid in cash, with the rest in the form of approximately 14.7mm Abcam shares (based on the pre-announcement ten-day average of £3.34 ($5.29)).
Deal Industry
- Contract Research, Toxicology Testing-CRO
- In Vitro Diagnostics
- Research, Analytical Equipment & Supplies
- Services
-
Laboratory Testing Services
- Anatomical Pathology
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Cash
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com